Hotgen(SH:688068) Sou Hu Cai Jing·2025-08-15 12:28Group 1 - The core viewpoint of the news is that Beijing Hotgen Biotech Co., Ltd. has experienced a decline in both revenue and net profit in its latest quarterly report, indicating potential challenges for the company [1] - As of August 15, 2025, Hotgen Biotech's stock closed at 227.5 yuan, down 0.35%, with a trading volume of 20,600 lots and a transaction amount of 465 million yuan [1] - The company's total revenue for the first quarter of 2025 was 93.24 million yuan, a year-on-year decrease of 19.71%, while the net profit attributable to shareholders was 24.01 million yuan, a significant drop of 574.96% [1] Group 2 - Hotgen Biotech has made investments in 21 companies and participated in 448 bidding projects, showcasing its active engagement in the market [2] - The company holds 85 trademark registrations and 88 patents, indicating a focus on intellectual property development [2] - Additionally, Hotgen Biotech has obtained 176 administrative licenses, reflecting its compliance and operational capabilities [2]